Story perspectives

GLP-1 Medications Cut Cancer Risk by 17% in Obesity

8/29/2025

42 8

Summary

Story summary

A study indicates that GLP-1 receptor agonists, such as Ozempic and Wegovy, lower cancer risk by 17% in obese individuals.
Significant reductions were observed in 12 of 13 obesity-related cancers, including ovarian and endometrial cancers.
Long-term use of GLP-1 medications is crucial for sustained weight loss and cancer risk reduction.
Experts stress the need for diet and exercise to maintain muscle mass and manage side effects.
High costs and insurance coverage issues may limit access to these medications for patients.

1 of 1

Story summary

A study indicates that GLP-1 receptor agonists, such as Ozempic and Wegovy, lower cancer risk by 17% in obese individuals.
Significant reductions were observed in 12 of 13 obesity-related cancers, including ovarian and endometrial cancers.
Long-term use of GLP-1 medications is crucial for sustained weight loss and cancer risk reduction.
Experts stress the need for diet and exercise to maintain muscle mass and manage side effects.
High costs and insurance coverage issues may limit access to these medications for patients.